Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.1%
    Check dated 2025-08-17T05:11:42.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.1%
    Check dated 2025-08-10T00:52:14.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    0.9%
    Check dated 2025-08-02T19:40:50.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.
    Difference
    0.2%
    Check dated 2025-07-26T15:57:10.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.5 to v2.16.6.
    Difference
    0.1%
    Check dated 2025-07-19T12:11:33.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    The web page now includes a service alert regarding planned maintenance starting July 25th, indicating that most services will be unavailable for over 24 hours beginning at 9 PM EDT.
    Difference
    0.9%
    Check dated 2025-07-12T08:11:51.000Z thumbnail image

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.